Abstract
CM is a new cephalosporine (CSP) with an expanded spectrum against gram negative organisms. 34 newborn infants (mean age 17 days, weight 3.6 kg), 32 with pustular skin infection and 2 with clinical sepsis (CS) were treated with 33 mg/kg of CM q 8 h IM for 7 days. Gentamicin was given to the 2 CS patients in addition. S. aureus (SA) was isolated in 25 cases and each was sensitive to CM. Blood cultures in all were sterile. All patients improved clinically and skin lesions disappeared by 5th day. The only side effects observed were transient elevation of SGOT (average 91, normal 40 units) in 11 and ↑ eosinophil counts (7%) in 9 cases. Coombs tests remained negative in all. Mean serum levels, half life (t 1/2) in minutes and volume distribution in ml/kg (Vd) following single doses in mg were as follows:
Blood levels were higher than reported for other CSP drugs and were many fold higher than MICs required in treatment of susceptible pathogens, including SA. T 1/2 and vds with different doses were comparable. Changes in eosinophil count and SGOT were similar to those of other CSP antibiotics.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Agbayani, M., Khan, A., Kemawikasit, P. et al. 749 CLINICAL AND PHARMACOLOGICAL EVALUATION OF CEFAMANDOLE (CM) IN NEONATAL INFECTIONS. Pediatr Res 12 (Suppl 4), 488 (1978). https://doi.org/10.1203/00006450-197804001-00754
Issue Date:
DOI: https://doi.org/10.1203/00006450-197804001-00754